A recent Medline search (January 2008) for articles related to PE, from 1949 to the present, uncovered a total of 589 references of which 160 articles (27%) had been published within the past 2 years. Much of this recent surge in interest has focused on new and promising medical relief for men who are troubled by this vexing condition. This review, while recognizing the critical importance of an integrated approach to the evaluation and management of PE—coordinating participation on the part of urologists, mental health professionals, endocrinologists, primary care physicians, and other interested healthcare professionals—is directed primarily at providing an update on recent developments in the medical treatment of PE. The definition of PE is still evolving, but the classic triad involved in the definition includes (i) short intravaginal ejaculatory latency time (IELT), (ii) lack of control, and (iii) sexual dissatisfaction [1]. The World Health Organization (WHO) 1994 International Classification of Diseases defines PE as “an inability to delay ejaculation sufficiently to enjoy lovemaking, manifest as either of the following: occurrence of ejaculation before or very soon after the beginning of intercourse (if a time limit is required: before or within 15 seconds of the beginning of intercourse); occurrence of ejaculation in the absence of sufficient erection to make intercourse possible.
The problem is not the result of prolonged absence from sexual activity” [1]. Furthermore, the WHO definition excludes men whose PE is predominately attributed to (i) alcohol, substance abuse, and/or medications; (ii) a sexual context that has led to very high levels of arousal because of the novelty of partner or situation; and (iii) a low frequency of sexual activity [1].
| Therapy Type | Description | Typical Duration | Success Rate | Noted Benefits | Noted Drawbacks |
|---|---|---|---|---|---|
| SSRI Medications | Selective serotonin reuptake inhibitors, delay ejaculation | 4-12 weeks | 70% | Long-term control | Possible side effects |
| Behavioral Therapy | Techniques like start-stop and squeeze method | Several sessions | 60-80% | No medication needed | Requires patient commitment |
| Topical Anesthetics | Numbing creams or sprays applied to glans penis | As needed | 65-75% | Fast onset | Reduced sensation, partner sensitivity |
| Pelvic Floor Exercises | Exercises to strengthen pubococcygeus muscles | 6-12 weeks | 50-65% | Improves control | Time-consuming |
Others have based their diagnosis on the number of penile thrusts occurring before ejaculation, considering less than 8–15 thrusts as the criterion for PE [2,3]. In 2007, responding to the variability of worldwide definitions and the need for a universal standard, the International Society for Sexual Medicine (ISSM) established an ad hoc committee consisting of 21 internationally recognized experts, to establish a new definition of PE. This latest ISSM definition, based on the recommendations of the most active and respected clinical and basic science experts in the field, characterized PE as follows: “Premature ejaculation is a male sexual dysfunction characterized by ejaculation which always or nearly always occurs prior to or within about one minute of vaginal penetration; and inability to delay ejaculation on all or nearly all vaginal penetrations; and negative personal consequences, such as distress, bother, frustration and/or the avoidance of sexual intimacy” [4]. Based on this new definition, some investigators may question the conclusions of previous studies with potentially inadequate patient selection definitions. Other related definitions include primary or lifelong PE—presence of the problem from the onset of initial sexual activity; acquired or late onset PE—indicates that the problem has developed after an initial time of unimpaired ejaculatory function; and situational (vs. global) PE—indicates PE that is limited to specific partner or situation, while the patient enjoys satisfactory intercourse in other contexts [5]. The National Health and Social Life Survey, a probability sample study of sexual behavior in men and women aged 18–59 years, reported a prevalence of 21% among men in the United States [6].
Nathan [7] analyzed the findings of 22 general population sex surveys, and estimated the prevalence of PE to be 35%.
This aerosol formulation is undergoing phase III trials in the United States, but is not Food and Drug Administration (FDA) approved at the time of this writing. So far, there has been an agreement neither on the amount of medication nor on the timeframe for its application. Recommended times for application have ranged from hour to 20 minutes prior to intercourse [29]. compared the application of EMLA cream 20, 30, and 45 minutes before intercourse, and found 20 minutes to be the optimum period before anticipated intercourse for topical application [30]. In a double-blinded, randomized, placebocontrolled study of 42 patients—lidocaineprilocaine vs.
placebo—the IELT improved with treatment from cheapest ed pills 1.49 to 8.45 minutes with lidocaine-prilocaine, while use of the placebo only increased the IELT from 0.7 to 1.9 minutes [31]. The application of an EMLA cream preparation—either lidocaine (2.5%) or prilocaine (2.5%)—20 to 30 minutes prior to intercourse has met with success [1]. In a placebo-controlled trial in 84 patients, when EMLA topical cream alone was compared with sildenafil alone or in combination with EMLA application, topical EMLA alone proved efficacious and had equal effectiveness to topical EMLA plus sildenafil therapy [2]. Similarly, a double-blind, randomized, placebocontrolled phase III clinical study of 106 patients with lifelong PE was conducted in three medical centers to investigate the efficacy of penile application of SS-cream. This herbal mixture, made from the extracts of nine natural products, was applied hour prior to intercourse and provided a dose-dependent clinical efficacy in 80% of men using the cream, as compared to 15% in the placebo group. Most estimates from other general population prevalence studies fall between 22% and 38%, with ranges from 4% to 39% [8–10].
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Cialis Generic | 20mg | 10 Pills | 31.49€ 29.99€ | |
| Cialis Generic | 5mg | 180 + 10 Pills | 159.65€ 152.05€ | |
| Levitra Professional | 20mg | 30 Pills | 119.12€ 113.45€ | |
| Viagra Professional | 100mg | 90 + 2 Pills | 207.09€ 197.23€ | |
| Kamagra Oral Jelly | 100mg | 220 + 18 Sachets | 662.24€ 630.70€ | |
| Kamagra Oral Jelly | 100 mg | 10 Sachets | 54.55€ 51.95€ | |
| Cialis Professional | 40mg | 120 + 4 Pills | 436.68€ 415.89€ | |
| Kamagra 100 mg | 100 mg | 60 + 4 Pills | 201.34€ 191.75€ | |
| Kamagra 100 mg | 100 mg | 20 Pills | 86.09€ 81.99€ | |
| Kamagra Gold | 100 mg | 360 + 6 Pills | 839.95€ 799.95€ |
The wide variability in the reported ranges is mirrored in the variability and lack of standardized definitions for PE. A number of studies have raised the point that in spite of the high prevalence rates, PE is the disorder for which patients are least likely to seek professional assistance, raising the distinct possibility that the problem may be more prevalent than currently estimated [8,10]. More recently, the PE Prevalence and Attitudes (PEPA) internetbased survey of 12,133 men aged 18–70 in the United States, Germany, and Italy reported a prevalence of 22.7% [11]. It is noteworthy that cenforce tablets only 9% of the men in this survey had consulted a physician, and more than 90% reported little or no improvement after they sought treatment, leading to a general lack of satisfaction with the results. It has also been suggested that the prevalence of PE may vary between racial groups; one recent survey of 1,320 men found that PE was more prevalently admitted among Hispanic men, highlighting the importance of further investigation of ethnic and cultural variances in PE worldwide [12]. The recurrent emerging pattern appears to be that PE is a largely underdiagnosed condition. The etiology of PE has been traditionally divided between “psychogenic” and “biogenic” factors. Psychogenic causes include anxiety, an unpleasant introductory or early sexual experience, infrequent sexual intercourse, poor ejaculatory control techniques, and evolutionary as well as psychodynamic factors. Urologic causes, including chronic prostatitis, have also been implicated [14]. Early animal studies revealed that nonselective agonists of the 5-HT2C receptors delay ejaculation, but selective 5-HT2A agonists do not have a similar effect, and selective 5-HT1A agonists cause a shorter ejaculatory latency compared with 5-HT2C agonists [15,16]. hypothesized that PE may be secondary to relative hyposensitivity of the 5-HT2C and/or 5-HT1A hypersensitivity [17]. The effect of postsynaptic 5-HT receptor activation on delayed ejaculation was later confirmed by using different selective serotonin reuptake inhibitors (SSRIs) [18–22]. The possible influence of genetic causes was investigated in a survey of 1,196 men in Finland that suggested the presence of a familial or genetic influence in 28% of men [23]. Decreasing sensory perception in the super p force 160mg penis has been the goal of most topical agents aimed at treating PE. As a general rule, reliable controlled studies have been lacking in this area.
A recent Medline search (January 2008) for articles related to PE, from 1949 to the present, uncovered a total of 589 references of which 160 articles (27%) had been published within the past 2 years. Much of this recent surge in interest has focused on new and promising medical relief for men who are troubled by this vexing condition. This review, while recognizing the critical importance of an integrated approach to the evaluation and management of PE—coordinating participation on the part of urologists, mental health professionals, endocrinologists, primary care physicians, and other interested healthcare professionals—is directed primarily at providing an update on recent developments in the medical treatment of PE. The definition of PE is still evolving, but the classic triad involved in the definition includes (i) short intravaginal ejaculatory latency time (IELT), (ii) lack of control, and (iii) sexual dissatisfaction [1]. The World Health Organization (WHO) 1994 International Classification of Diseases defines PE as “an inability to delay ejaculation sufficiently to enjoy lovemaking, manifest as either of the following: occurrence of ejaculation before or very soon after the beginning of intercourse (if a time limit is required: before or within 15 seconds of the beginning of intercourse); occurrence of ejaculation in the absence of sufficient erection to make intercourse possible.
The problem is not the result of prolonged absence from sexual activity” [1]. Furthermore, the WHO definition excludes men whose PE is predominately attributed to (i) alcohol, substance abuse, and/or medications; (ii) a sexual context that has led to very high levels of arousal because of the novelty of partner or situation; and (iii) a low frequency of sexual activity [1]. Others have based their diagnosis on the number of penile thrusts occurring before ejaculation, considering less than 8–15 thrusts as the criterion for PE [2,3]. In 2007, responding to the variability of worldwide definitions and the need for a universal standard, the International Society for Sexual Medicine (ISSM) established an ad hoc committee consisting of 21 internationally recognized experts, to establish a new definition of PE. This latest ISSM definition, based on the recommendations of the most active and respected clinical and basic science experts in the field, characterized PE as follows: “Premature ejaculation is a male sexual dysfunction characterized by ejaculation which always or nearly always occurs prior to or within about one minute of vaginal penetration; and inability to delay ejaculation on all or nearly all vaginal penetrations; and negative personal consequences, such as distress, bother, frustration and/or the avoidance of sexual intimacy” [4]. Penile biothesiometry studies have shown that patients with PE have increased penile sensitivity as shown by consistently decreased vibratory threshold that is not age dependent [24,25].
IELT increased to greater than 2 minutes. After treatment, the mean ejaculatory latency was prolonged to 2.45 +/– 0.29 minutes in the placebo group, and 10.92 +/– 0.95 minutes in the SS-cream group [32]. General objections to all forms of topical therapy include complaints of significant penile hypoanesthesia and risk of transvaginal absorption with vaginal numbness, unless a condom is utilized [1]. Irritating topical reactions, both penile and vaginal, can occur, and systemic reactions are also possible [31]. Efforts to wash off the medication prior to intercourse may reduce the risk of these side effects, but also reduce the spontaneity of the coital experience [12,33]. Lidocaine- or prilocaine-based sprays, creams, or gels, as well as eutectic (i.e., melts easily) mixtures, have shown promise [26,27]. Their application offers a rapid onset of effect, with relatively mild numbness. A typically mild adverse side effects profile and availability for on-demand usage are other advantages in this category. In 9 of 11 men with PE, prilocaine-lidocaine cream (EMLA [eutectic mixture of local anesthetics], Astra Pharmaceuticals, Wayne, PA, USA) was shown to markedly improve IELT without any reported adverse events [28]. In phase II testing, topical eutectic mixture for PE (TEMPE), when used as an aerosol 15 minutes before intercourse, resulted in a 3.8 minute increased in IELT, compared to 0.7 minutes for the placebo.
As a general rule, reliable controlled studies have been lacking in this area. Penile biothesiometry studies have shown that patients with PE have increased penile sensitivity as shown by consistently decreased vibratory threshold that is not age dependent [24,25]. Lidocaine- or prilocaine-based sprays, creams, or gels, as well as eutectic (i.e., melts easily) mixtures, have shown promise [26,27]. Their application offers a rapid onset of effect, with relatively mild numbness. A typically mild adverse side effects profile and availability for on-demand usage are other advantages in this category.
In 9 of 11 men with PE, prilocaine-lidocaine cream (EMLA [eutectic mixture of local anesthetics], Astra Pharmaceuticals, Wayne, PA, USA) was shown to markedly improve IELT without any reported adverse events [28]. In phase II testing, topical eutectic mixture for PE (TEMPE), when used as an aerosol 15 minutes before intercourse, resulted in a 3.8 minute increased in IELT, compared to 0.7 minutes for the placebo. While this constituted a 2.4-fold improvement over placebo, the numbers were too small to establish a statistically significant difference [27]. The topical application of anesthetic creams has the disadvantage of requiring a somewhat messy application within a condom, and the entire shaft is anesthetized. Aerosol TEMPE formulation, on the other hand, requires a decreased time for prior application, and only the glans penis is anesthetized [27,29]. While this constituted a 2.4-fold improvement over placebo, the numbers were too small to establish a statistically significant difference [27]. The topical application of anesthetic creams has the disadvantage of requiring a somewhat messy application within a condom, and the entire shaft is anesthetized.
Aerosol TEMPE formulation, on the other hand, requires a decreased time for prior application, and only the glans penis is anesthetized [27,29]. This aerosol formulation is undergoing phase III trials in the United States, but is not Food and Drug Administration (FDA) approved at the time of this writing. So far, there has been an agreement neither on the amount of medication nor on the timeframe for its application. Recommended times for application have ranged from hour to 20 minutes prior to intercourse [29].
compared the application of EMLA cream 20, 30, and 45 minutes before intercourse, and found 20 minutes to be the optimum period before anticipated intercourse for topical application [30]. In a double-blinded, randomized, placebocontrolled study of 42 patients—lidocaineprilocaine vs. placebo—the IELT improved with treatment from cheapest ed pills 1.49 to 8.45 minutes with lidocaine-prilocaine, while use of the placebo only increased the IELT from 0.7 to 1.9 minutes [31]. The application of an EMLA cream preparation—either lidocaine (2.5%) or prilocaine (2.5%)—20 to 30 minutes prior to intercourse has met with success [1]. In a placebo-controlled trial in 84 patients, when EMLA topical cream alone was compared with sildenafil alone or in combination with EMLA application, topical EMLA alone proved efficacious and had equal effectiveness to topical EMLA plus sildenafil therapy [2].
Based on this new definition, some investigators may question the conclusions of previous studies with potentially inadequate patient selection definitions. Other related definitions include primary or lifelong PE—presence of the problem from the onset of initial sexual activity; acquired or late onset PE—indicates that the problem has developed after an initial time of unimpaired ejaculatory function; and situational (vs. global) PE—indicates PE that is limited to specific partner or situation, while the patient enjoys satisfactory intercourse in other contexts [5]. The National Health and Social Life Survey, a probability sample study of sexual behavior in men and women aged 18–59 years, reported a prevalence of 21% among men in the United States [6]. Nathan [7] analyzed the findings of 22 general population sex surveys, and estimated the prevalence of PE to be 35%.
Most estimates from other general population prevalence studies fall between 22% and 38%, with ranges from 4% to 39% [8–10]. The wide variability in the reported ranges is mirrored in the variability and lack of standardized definitions for PE. A number of studies have raised the point that in spite of the high prevalence rates, PE is the disorder for which patients are least likely to seek professional assistance, raising the distinct possibility that the problem may be more prevalent than currently estimated [8,10]. More recently, the PE Prevalence and Attitudes (PEPA) internetbased survey of 12,133 men aged 18–70 in the United States, Germany, and Italy reported a prevalence of 22.7% [11]. It is noteworthy that cenforce tablets only 9% of the men in this survey had consulted a physician, and more than 90% reported little or no improvement after they sought treatment, leading to a general lack of satisfaction with the results. Similarly, a double-blind, randomized, placebocontrolled phase III clinical study of 106 patients with lifelong PE was conducted in three medical centers to investigate the efficacy of penile application of SS-cream. This herbal mixture, made from the extracts of nine natural products, was applied hour prior to intercourse and provided a dose-dependent clinical efficacy in 80% of men using the cream, as compared to 15% in the placebo group. IELT increased to greater than 2 minutes. After treatment, the mean ejaculatory latency was prolonged to 2.45 +/– 0.29 minutes in the placebo group, and 10.92 +/– 0.95 minutes in the SS-cream group [32].
It has also been suggested that the prevalence of PE may vary between racial groups; one recent survey of 1,320 men found that PE was more prevalently admitted among Hispanic men, highlighting the importance of further investigation of ethnic and cultural variances in PE worldwide [12]. The recurrent emerging pattern appears to be that PE is a largely underdiagnosed condition. The etiology of PE has been traditionally divided between “psychogenic” and “biogenic” factors. Psychogenic causes include anxiety, an unpleasant introductory or early sexual experience, infrequent sexual intercourse, poor ejaculatory control techniques, and evolutionary as well as psychodynamic factors. Urologic causes, including chronic prostatitis, have also been implicated [14].
Early animal studies revealed that nonselective agonists of the 5-HT2C receptors delay ejaculation, but selective 5-HT2A agonists do not have a similar effect, and selective 5-HT1A agonists cause a shorter ejaculatory latency compared with 5-HT2C agonists [15,16]. hypothesized that PE may be secondary to relative hyposensitivity of the 5-HT2C and/or 5-HT1A hypersensitivity [17]. The effect of postsynaptic 5-HT receptor activation on delayed ejaculation was later confirmed by using different selective serotonin reuptake inhibitors (SSRIs) [18–22]. The possible influence of genetic causes was investigated in a survey of 1,196 men in Finland that suggested the presence of a familial or genetic influence in 28% of men [23]. Decreasing sensory perception in the super p force 160mg penis has been the goal of most topical agents aimed at treating PE. General objections to all forms of topical therapy include complaints of significant penile hypoanesthesia and risk of transvaginal absorption with vaginal numbness, unless a condom is utilized [1]. Irritating topical reactions, both penile and vaginal, can occur, and systemic reactions are also possible [31]. Efforts to wash off the medication prior to intercourse may reduce the risk of these side effects, but also reduce the spontaneity of the coital experience [12,33].